{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:44:53Z","timestamp":1793108693007,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012007","name":"Rockefeller University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012007","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI175771"],"award-info":[{"award-number":["R01AI175771"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["R01AI177473"],"award-info":[{"award-number":["R01AI177473"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["U19AI057229"],"award-info":[{"award-number":["U19AI057229"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006492","name":"National Institute of Allergy and Infectious Diseases Division of Intramural Research","doi-asserted-by":"publisher","award":["R01AI178298"],"award-info":[{"award-number":["R01AI178298"]}],"id":[{"id":"10.13039\/100006492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunity"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.immuni.2026.03.028","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T15:14:22Z","timestamp":1777043662000},"page":"2030-2040.e7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacologic glycoengineering of Fc\u03b3 receptor IIIa enhances force-resistant IgG-Fc\u03b3R interactions and anti-tumor antibody efficacy"],"prefix":"10.1016","volume":"59","author":[{"given":"Bowie Yik-Ling","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel M.","family":"Centeio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Kung-Chun","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casey L.","family":"Kiyohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Herzog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rony","family":"Dahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy E.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3894-685X","authenticated-orcid":false,"given":"Taia T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.immuni.2026.03.028_bib1","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.4049\/jimmunol.1490027","article-title":"Translational medicine in action: anti-CD20 therapy in lymphoma","volume":"193","author":"Lim","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib2","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/nrc3236","article-title":"Antibody therapy of cancer","volume":"12","author":"Scott","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.immuni.2026.03.028_bib3","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1158\/2767-9764.CRC-24-0638","article-title":"Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid Tumors","volume":"5","author":"Gambardella","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"10.1016\/j.immuni.2026.03.028_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by Antibodies: Recent Progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib5","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.molmed.2024.10.008","article-title":"Fc-optimized checkpoint antibodies for cancer immunotherapy","volume":"31","author":"Dahan","year":"2025","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.immuni.2026.03.028_bib6","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.immuni.2025.05.008","article-title":"Cytotoxic IgG: Mechanisms, functions, and applications","volume":"58","author":"W\u00f6hner","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.03.028_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/1074-7613(95)90155-8","article-title":"Cytotoxic antibodies trigger inflammation through Fc receptors","volume":"3","author":"Clynes","year":"1995","journal-title":"Immunity"},{"key":"10.1016\/j.immuni.2026.03.028_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/imr.13109","article-title":"Heterogeneity in IgG-CD16 signaling in infectious disease outcomes","volume":"309","author":"Gonzalez","year":"2022","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.immuni.2026.03.028_bib9","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abm7853","article-title":"Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity","volume":"14","author":"Chakraborty","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.immuni.2026.03.028_bib10","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall'Ozzo","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2026.03.028_bib11","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1074\/jbc.M510171200","article-title":"The carbohydrate at FcgammaRIIIa Asn-162: An element required for high affinity binding to non-fucosylated IgG glycoforms","volume":"281","author":"Ferrara","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.immuni.2026.03.028_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/science.abl5282","article-title":"Tuning T cell receptor sensitivity through catch bond engineering","volume":"376","author":"Zhao","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.immuni.2026.03.028_bib13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0092-8674(91)90393-D","article-title":"Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins","volume":"65","author":"Lawrence","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.03.028_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012391","article-title":"Tumor glyco-immunology, glyco-immune checkpoints and immunotherapy","volume":"13","author":"Pinho","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.immuni.2026.03.028_bib15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1158\/2326-6066.CIR-20-0264","article-title":"Glycans as Immune Checkpoints: Removal of Branched N-glycans Enhances Immune Recognition Preventing Cancer Progression","volume":"8","author":"Silva","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.immuni.2026.03.028_bib16","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41423-024-01142-0","article-title":"Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2","volume":"21","author":"Wieboldt","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nchembio.1388","article-title":"Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion","volume":"10","author":"Hudak","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.immuni.2026.03.028_bib18","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215376120","article-title":"MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint","volume":"120","author":"Smith","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.03.028_bib19","doi-asserted-by":"crossref","DOI":"10.1172\/JCI180282","article-title":"Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer","volume":"134","author":"Wen","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.immuni.2026.03.028_bib20","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1074\/jbc.RA118.004998","article-title":"CD16a with oligomannose-type N-glycans is the only \"low-affinity\" Fc gamma receptor that binds the IgG crystallizable fragment with high affinity in vitro","volume":"293","author":"Subedi","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.immuni.2026.03.028_bib21","article-title":"One N-glycan regulates natural killer cell antibody-dependent cell-mediated cytotoxicity and modulates Fc gamma receptor IIIa \/ CD16a structure","author":"Kremer","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.immuni.2026.03.028_bib22","first-page":"1450","article-title":"A phase I study of swainsonine in patients with advanced malignancies","volume":"54","author":"Goss","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.immuni.2026.03.028_bib23","first-page":"1077","article-title":"Phase IB clinical trial of the oligosaccharide processing inhibitor swainsonine in patients with advanced malignancies","volume":"3","author":"Goss","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.immuni.2026.03.028_bib24","doi-asserted-by":"crossref","first-page":"11596","DOI":"10.1074\/jbc.M707815200","article-title":"FimH forms catch bonds that are enhanced by mechanical force due to allosteric regulation","volume":"283","author":"Yakovenko","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.immuni.2026.03.028_bib25","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0092-8674(02)00796-1","article-title":"Bacterial adhesion to target cells enhanced by shear force","volume":"109","author":"Thomas","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.03.028_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/35018508","article-title":"The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex","volume":"406","author":"Sondermann","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.immuni.2026.03.028_bib27","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/glycob\/cwn110","article-title":"The N-linked oligosaccharide at Fc gamma RIIIa Asn-45: an inhibitory element for high Fc gamma RIIIa binding affinity to IgG glycoforms lacking core fucosylation","volume":"19","author":"Shibata-Koyama","year":"2009","journal-title":"Glycobiology"},{"key":"10.1016\/j.immuni.2026.03.028_bib28","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1182\/blood.V84.8.2457.2457","article-title":"Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma","volume":"84","author":"Maloney","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2026.03.028_bib29","first-page":"63","article-title":"IgG Fc Glycosylation in Human Immunity","volume":"423","author":"Wang","year":"2019","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.cell.2015.06.026","article-title":"Anti-HA Glycoforms Drive B Cell Affinity Selection and Determine Influenza Vaccine Efficacy","volume":"162","author":"Wang","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.03.028_bib31","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the FcgammaRIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2026.03.028_bib32","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.immuni.2026.03.028_bib33","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fcgamma receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.immuni.2026.03.028_bib34","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","article-title":"Differential Fc-Receptor Engagement Drives an Anti-tumor Vaccinal Effect","volume":"161","author":"DiLillo","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.immuni.2026.03.028_bib35","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.immuni.2026.03.028_bib36","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the First-Line Treatment of Follicular Lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.immuni.2026.03.028_bib37","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.immuni.2026.03.028_bib38","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00441-008-0706-5","article-title":"Arterial versus venous endothelial cells","volume":"335","author":"dela Paz","year":"2009","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.immuni.2026.03.028_bib39","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1146\/annurev-immunol-082423-035904","article-title":"Catch Bonds in Immunology","volume":"43","author":"Choi","year":"2025","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib40","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/s41590-019-0491-1","article-title":"Mechanosensing through immunoreceptors","volume":"20","author":"Zhu","year":"2019","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.immuni.2026.03.028_bib41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/j.bpj.2018.04.002","article-title":"How Do We Know when Single-Molecule Force Spectroscopy Really Tests Single Bonds?","volume":"114","author":"Johnson","year":"2018","journal-title":"Biophys. J."},{"key":"10.1016\/j.immuni.2026.03.028_bib42","doi-asserted-by":"crossref","first-page":"10304","DOI":"10.1073\/pnas.1608069113","article-title":"Precision glycocalyx editing as a strategy for cancer immunotherapy","volume":"113","author":"Xiao","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326001391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1074761326001391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:29:20Z","timestamp":1793107760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1074761326001391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1074761326001391"],"URL":"https:\/\/doi.org\/10.1016\/j.immuni.2026.03.028","relation":{},"ISSN":["1074-7613"],"issn-type":[{"value":"1074-7613","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic glycoengineering of Fc\u03b3 receptor IIIa enhances force-resistant IgG-Fc\u03b3R interactions and anti-tumor antibody efficacy","name":"articletitle","label":"Article Title"},{"value":"Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.immuni.2026.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}